BACK

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Fluoropyrimidine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (D9803C00001 (CLARITY-Gastric 02))